GLG News by Oncologists Specializing in Hematologic Malignancies in the U.S.

Proteolix's selective proteosome inhibitor PR-171 have shown pre-clinical activity in slid tumor animal models, but only a small Phase Ib clinical trial of 14 patients have been completed. based on spectrum of activity of a similar compound ( Valcade, Mellinium), the main efficacy of this agent...

Cancer patients frequently develop neuropathy as a results of chemotherapy agents including oxaliplatin, paclitaxel, vinca alkaloids, and Velcade.  Because many such patients have extended survival or receive treatment with curative intent, the resultant neuropathy can limit quality of life significantly....

Carfilzomib is a nvelo prteosome inhibitor.  Bortezomib, the only proteosome inhibitor that is currently FDA approve, has shown significant activity in myeloma and mantle cell NHL and is being tested in other hematologic malignancies.  If Carfilzomib has improved toxicty and greater efficacy...

The ease of use compared to fludarabine regimens, and the superior efficacy vs chlorambucil, puts TREANDA in the sweet spot for potential front-line use in CLL.

National healthcare has again become part of the presidential election dialog, after a curious 12+ year absence. Also curious, Hillary Clinton is again center stage in the discussion. Will the outcome be different this time?

The aging population, coupled with per capita decreases in Medicare spending, threatens the entire health care system. Here's why.

Ricin is an extraordinarily potent toxin that is fatal because of its ability to inhibit protein synthesis and rapidly cause multisystem failure.  Because ricin can be prepared from castro beans, it has the potential to be used in terrorist attacks.  The present vaccine has the potential to...

Vargatef is a novel angiokinase inhibitor that blocks VEGF, PDGR and FGF receptors.  The current phase II study in patients with non small cell lung cancer shows that this oral agent can be given safely.  It is far too early to draw conclusions regarding efficacy.

Micromet's Bite antibodies strategy garners the patient's T-cells to attack tumor cells. This technology showed proof of principle i hematological malignancies , and now a Phase I clinical trial has commenced for solid tumors. The rationale is intriguing, but immunotherapy has been elusive in solid...

Xeloda, an oral agent, was non-inferior to infusional 5-FU, when combined ith oxaliplatin in a randomized trial in patients with metastatic colrectal cancer (m-CRC) In fact, Xeloda containing regimen was assocaited with less myelosuppression, but more rashes and diaarhea. This is good news for...